Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810166 | 0.90 | CYP3A4 (0.33) | CYP3A4ALDH1A1KDM4ETSHRSMN1; SMN2 | |
| SCHEMBL14809136 | 0.86 | MAPT (0.37) | CYP3A4ALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL14823828 | 0.84 | CYP3A4 (0.36) | CYP3A4ALDH1A1KDM4E | |
| SCHEMBL16252243 | 0.84 | CYP3A4 (0.36) | CYP3A4ALDH1A1KDM4EMAPT | |
| SCHEMBL14810111 | 0.84 | MAPT (0.39) | CYP3A4ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL14809798 | 0.84 | CYP3A4 (0.36) | CYP3A4MAPT | |
| SCHEMBL14810084 | 0.84 | CYP3A4 (0.36) | CYP3A4ALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL14809836 | 0.83 | MAPT (0.36) | CYP3A4ALDH1A1POLBMAPT | |
| SCHEMBL16252239 | 0.82 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL14810135 | 0.82 | CYP3A4 (0.34) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | CYP3A4 573/4885ALDH1A1 3281/4885KDM4E 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.